DUBLIN, Apr. 16, 2015 /PRNewswire/ --Research and Markets

(http://www.researchandmarkets.com/research/qvd3lm/cancer_growth) has announced the addition of the "Cancer Growth Inhibitors Market & Clinical Pipeline Analysis " report to their offering.

Cancer growth inhibitors market shows overlapping boundaries due to which it becomes difficult to demarcate different categories. For instance, a tyrosine kinase may be a small molecules or a large molecule because they have same inhibitory molecule. On the other hand, they may inhibit cellular processes and belong to different molecular classes. Despite these differences, cancer growth inhibitors occupy large market shares and targeted therapeutics seems to be the major contenders.

They have high safety and efficacy profiles along with minimized side effects due to which large number of patients are including them as a part of their regular therapeutic regime. In coming years, they are expected to become main focus of pharmaceutical companies because conventional cancer therapies like chemotherapy have proved to have modest efficacy. In future, their therapeutic efficacy is expected to increase and many innovative products are at different phases of clinical development due to which their global market is expected to witness steady growth.

Clinical pipeline of cancer growth inhibitors is increasing due to innovations and potential competition from newly developed cancer drugs. Pharmaceutical companies are focusing on approaches like utilization of next generation sequencing and computerized simulation to prevent undue wastage of time and resources. Relapse is another biggest issues associated with conventional cancer therapeutics which could be prevented with the help of cancer growth inhibitors. Innovative cancer growth inhibitors are expected to increase average survival time and decrease mortality rates.

These factors are expected to increase the demand for cancer growth inhibitors but still lots of modalities have to be streamlined in order to offer sustainable competition to newly coming cancer therapeutics belonging to other drug categories. One of the major steps in order to overcome these shortcomings could be the utilization of high end technology.

Cancer Growth Inhibitors Covered in Report:

- Cancer Tyrosine Kinase
- Proteasome Inhibitors
- MTOR Protein Inhibitors
- Histone Deacetylase Inhibitors (HDAC inhibitors)
- PI3k

Cancer Growth Inhibitors Market & Clinical Pipeline Analysis Report Highlight:

- Introduction & Classification of Cancer Growth Inhibitors
- Cancer Growth Inhibitors Clinical Pipeline by Company, Indication & Phase
- Cancer Growth Inhibitors Clinical Pipeline: 629 Drugs
- Markets Cancer Growth Inhibitors: 48 Drugs
- Tyrosine Kinase Dominates Cancer Growth Inhibitors Pipeline: 394 Drugs
- HDAC Inhibitors Clinical Pipeline: 65 Drugs
- MTOR Protein Inhibitors Clinical Pipeline: 62 Drugs
- PI3k Clinical Pipeline: 89 Drugs
- Proteasome Inhibitors Clinical Pipeline: 19 Drugs
- Global Cancer Growth Inhibitors Market Future Prospects

Companies Mentioned

- Advaxis
- Amgen
- AstraZeneca
- Bristol Mayer Squibb
- Celldex Therapeutics
- Eli Lily
- GalaxoSmithKline
- Genetech.ImmunoCellular Therapeutics
- ImmunoGen
- Merck
- Novartis
- Pfizer
- Roche
- Sanofi
- Teva

For more information visit http://www.researchandmarkets.com/research/qvd3lm/cancer_growth

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

Related Links

http://www.researchandmarkets.com

SOURCE Research and Markets